A randomized, double-blind, placebo-controlled trial comparing the efficacy and tolerance of solriamfetol in patients affected with idiopathic hypersomnia. SOLR-IH

2024-513365-39-00 Protocol RECMPL23_0432 Therapeutic exploratory (Phase II) Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol RECMPL23_0432

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Authorised, recruitment pending
Participants planned 60
Countries 1
Sites 1

idiopathic hypersomnia

Key facts

Sponsor
Centre Hospitalier Universitaire De Montpellier
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Decision date (initial)
2024-07-11
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

idiopathic hypersomnia

VersionLevelCodeTermSystem organ class
21.1 LLT 10075058 Idiopathic hypersomnia 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Montpellier

Sponsor organisation
Centre Hospitalier Universitaire De Montpellier
Address
191 Avenue Du Doyen Gaston Giraud
City
Montpellier Cedex 5
Postcode
34295
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Montpellier
Contact name
Amelle ISSA

Public contact point

Organisation
Centre Hospitalier Universitaire De Montpellier
Contact name
Amelle ISSA

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 60 1
Rest of world 0

Investigational sites

France

1 site · Authorised, recruitment pending
Centre Hospitalier Universitaire De Montpellier
Neurologie, 191 Avenue Du Doyen Gaston Giraud, 34295, Montpellier Cedex 5

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-05 France Acceptable
2024-07-10
2024-07-11
2 SUBSTANTIAL MODIFICATION SM-1 2025-06-06 France Acceptable
2025-07-15
2025-08-07